These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16652058)

  • 1. Individual, interpersonal, and structural correlates of effective HAART use among urban active injection drug users.
    Knowlton A; Arnsten J; Eldred L; Wilkinson J; Gourevitch M; Shade S; Dowling K; Purcell D;
    J Acquir Immune Defic Syndr; 2006 Apr; 41(4):486-92. PubMed ID: 16652058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral use among active injection-drug users: the role of patient-provider engagement and structural factors.
    Knowlton AR; Arnsten JH; Eldred LJ; Wilkinson JD; Shade SB; Bohnert AS; Yang C; Wissow LS; Purcell DW
    AIDS Patient Care STDS; 2010 Jul; 24(7):421-8. PubMed ID: 20578910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microsocial environmental influences on highly active antiretroviral therapy outcomes among active injection drug users: the role of informal caregiving and household factors.
    Knowlton AR; Arnsten JH; Gourevitch MN; Eldred L; Wilkinson JD; Rose CD; Buchanan A; Purcell DW;
    J Acquir Immune Defic Syndr; 2007 Nov; 46 Suppl 2():S110-9. PubMed ID: 18089980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
    Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
    Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
    Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
    CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.
    Larsen MV; Omland LH; Gerstoft J; Røge BT; Larsen CS; Pedersen G; Obel N; Kronborg G
    Scand J Infect Dis; 2010 Dec; 42(11-12):917-23. PubMed ID: 20840000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users.
    Altice FL; Springer S; Buitrago M; Hunt DP; Friedland GH
    J Urban Health; 2003 Sep; 80(3):416-27. PubMed ID: 12930880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe food insecurity is associated with elevated unprotected sex among HIV-seropositive injection drug users independent of HAART use.
    Shannon K; Kerr T; Milloy MJ; Anema A; Zhang R; Montaner JS; Wood E
    AIDS; 2011 Oct; 25(16):2037-42. PubMed ID: 21811140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in sexual and drug-related risk behavior following antiretroviral therapy initiation among HIV-infected injection drug users.
    Fu TC; Westergaard RP; Lau B; Celentano DD; Vlahov D; Mehta SH; Kirk GD
    AIDS; 2012 Nov; 26(18):2383-91. PubMed ID: 23079804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.
    Celentano DD; Galai N; Sethi AK; Shah NG; Strathdee SA; Vlahov D; Gallant JE
    AIDS; 2001 Sep; 15(13):1707-15. PubMed ID: 11546947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of short-term adherence on virological and immunological success of HAART: a case study among French HIV-infected IDUs.
    Pradier C; Carrieri P; Bentz L; Spire B; Dellamonica P; Moreau J; Moatti JP
    Int J STD AIDS; 2001 May; 12(5):324-8. PubMed ID: 11368807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use.
    Palepu A; Tyndall M; Yip B; O'Shaughnessy MV; Hogg RS; Montaner JS
    J Acquir Immune Defic Syndr; 2003 Apr; 32(5):522-6. PubMed ID: 12679704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly active antiretroviral therapy and survival in HIV-infected injection drug users.
    Wood E; Hogg RS; Lima VD; Kerr T; Yip B; Marshall BD; Montaner JS
    JAMA; 2008 Aug; 300(5):550-4. PubMed ID: 18677027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for survival differ according to CD4+ cell count among HIV-infected injection drug users: pre-HAART and HAART eras.
    Galai N; Vlahov D; Bareta JC; Wang C; Cohn S; Sterling TR
    J Acquir Immune Defic Syndr; 2005 Jan; 38(1):74-81. PubMed ID: 15608529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
    Rodríguez-Arenas MA; Jarrín I; del Amo J; Iribarren JA; Moreno S; Viciana P; Peña A; Sirvent JL; Vidal F; Lacruz J; Gutierrez F; Oteo JA; Asencio R; Castilla J; Hoyos SP;
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating supervised HAART in late-stage HIV among drug users: a preliminary report.
    Greenberg B; Berkman A; Thomas R; Hoos D; Finkelstein R; Astemborski J; Vlahov D
    J Urban Health; 1999 Dec; 76(4):468-80. PubMed ID: 10609596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poorer physical health-related quality of life among Aboriginals and injection drug users treated with highly active antiretroviral therapy.
    Martin LJ; Houston S; Yasui Y; Wild TC; Saunders LD
    Can J Public Health; 2012 Nov; 104(1):e33-8. PubMed ID: 23618106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.